ZCCHC4 and neoplasm: The present findings offer compelling evidence that ZCCHC4 emerges as a promising candidate biomarker, complementary to established tumor markers, and may contribute to a more comprehensive molecular profiling strategy for ESCC diagnosis and prognosis.